Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT03516617RecruitingPhase 2
Acalabrutinib with or without obinutuzumab for early CLL/SLL
This Phase 2 trial studies whether acalabrutinib, and optionally adding obinutuzumab, can control early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see how well these treatments work and how safe they are in people who have not had prior treatment.
Scottsdale, ArizonaAges 18 years+ - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65 - NCT03524222Recruiting
Home hospital care for adults after sudden illness
This trial tests whether certain adults can safely receive hospital-level care at home instead of staying in the hospital, using a home care team. It may help you recover in your own home if your condition fits their plan and you have support at home.
Boston, MassachusettsAges 18 years+ - NCT03568266Recruiting
Genetic study of liver injury from a leukemia medicine
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
Los Angeles, CaliforniaAges 18 years+ - NCT03539692Recruiting
Screening to join food allergy tests with a food challenge
This study checks whether you’re a safe and willing candidate to take part in food allergy clinical studies at one location. It helps decide who can safely undergo the “gold standard” food challenge to confirm or rule out food allergy.
Palo Alto, CaliforniaAges 1 week–90 years - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT03621553RecruitingPhase 4
Vitamin D balance study in people with sarcoidosis
This Phase 4 study looks at how your body keeps vitamin D levels balanced in sarcoidosis. It may help researchers understand what affects calcium and vitamin D in sarcoidosis, and guide safer care.
Dallas, TexasAges 21 years+ - NCT03308474Recruiting
Myeloma patient registry study for treatment experiences
This trial enrolls people with multiple myeloma who are starting (or have recently started) standard drug treatment, so researchers can collect real-world information about patients’ experiences and outcomes. It may help by improving future care planning and study designs, while adding an extra set of questionnaires to your routine.
Multiple SitesAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Phoenix, ArizonaAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Tucson, ArizonaAges 18 years+ - NCT03300830Recruiting
Testing tumors linked to viruses, HIV, and immune disorders
This study collects and analyzes tumor tissue to learn what drives certain cancers and growths linked to viruses, HIV, and immune system problems. Results may help researchers understand disease causes and point to better future treatments.
Bethesda, MarylandAges 18 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT03414502RecruitingPhase 3
Predictors of Response to DMARDs in Rheumatoid Arthritis
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
Omaha, NebraskaAges 19 years+ - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT03422614Recruiting
Study immune-system disorders in people with primary immune problems
This study looks at what is happening in the immune system for people with an inherited (primary) immune problem. It may help researchers better understand the disease and how it works.
ZurichAges Any age - NCT03458429Enrolling by invitationPhase 1/Phase 2
Plasma from healthy donors for frailty and immune health
This Phase 1/2 study tests whether transfusions of donated plasma can improve frailty and immune function in older adults. It mainly checks safety first, and also looks for signs that the immune system and overall strength may improve.
Boynton Beach, FloridaAges 55–95 - NCT03505216Recruiting
Child lung symptom clinic registry for Swiss families
This study collects information from children and teens (up to age 16) who are seen in a children’s lung clinic for breathing or respiratory problems in Switzerland. The goal is to better understand these conditions in everyday care, which may help improve future diagnosis and treatment.
ViennaAges birth–16 years - NCT03369353Enrolling by invitation
Personalized immune testing study for bowel and transplant patients
This study looks at whether a precise lab test can help understand inflammatory bowel disease, functional gut disorders, and immune changes after stem cell transplant or cell therapy. It may help doctors choose better monitoring and treatments based on your immune and gut test results.
Boston, MassachusettsAges Any age - NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for lymphoma and blood disorders
This trial tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy helps treat lymphomas that have come back or not responded, as well as two related blood disorders (CCUS and CMML). The goal is to see if the vitamin C makes the chemo work better.
Mankato, MinnesotaAges 18 years+ - NCT03399175Recruiting
Early immune-suppressing treatment for VKH eye disease
This trial studies giving immune-suppressing treatment early in Vogt-Koyanagi-Harada (VKH) disease to see if it improves outcomes. It may help people reduce ongoing eye inflammation if they qualify and can be followed for a longer time.
São Paulo, São PauloAges 10–70 - NCT03458520Recruiting
Kid PET/MR scan registry for solid tumor imaging
This study is a registry that collects images from children (and some adults) with suspected or confirmed solid tumors to help researchers learn how best to use PET/MR scans. It may help future patients by improving imaging and diagnosis planning.
Palo Alto, CaliforniaAges Up to 40 years - NCT03478670Enrolling by invitation
Registry follow-up for ADA-SCID patients treated with Strimvelis
This study keeps track of people with ADA-SCID (a rare immune system condition) who previously received Strimvelis or a related treatment. It helps doctors understand long-term outcomes and safety after treatment.
Milan, LombardyAges Any age
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.